Diseases
Antihypertensives
Competitor Analysis
| Publication Date | June 2008 |
| Publisher | La Merie |
| Product Type | Report |
| Pages | 18 |
| ISBN Number | not applicable |
| Product Code | LME00041 |
Price
approximately: $386 | €297
PDF immediate delivery
Order above formats by FAX
Summary
Product description
The Competitive Intelligence Report Antihypertensives as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of pulmonary artery hypertension, arterial hypertension, portal hypertension and intradialytic hypertension. The report also provides information about the market size of the largest drug class for treatment of arterial hypertension, i.e. angiotensin receptor blockers. Among the companies active in the field of new antihypertensives are Sanofi-Aventis, Daiichi-Sankyo, Bristol-Myers Squibb, GlaxoSmithKline, AstraZeneca, Pfizer, Bayer Schering Pharma, Eli Lilly, Takeda Pharmaceuticals, Novartis and many others.
The report includes a compilation of current active projects in research and development of novel antihypertensives.
Competitor projects are listed in a tabular format providing Information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Contents
- Index
- Pulmonary artery hypertension
- Arterial hypertension
- Angiotensin Recpetor Blockers
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Endothelin Receptor Antagonists
- Calcium Channel Blockers
- Beta and Alpha Blockers
- Phosphodiesterase5 (PDE5) Inhibitors
- Renin Inhibitors
- New Targets
- Portal hypertension, intradialytic hypertension
- About La Merie
